Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYSA1801 in CLDN 18.2 Positive Advanced Solid Tumors
NCT05009966Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYSA1801 in solid tumor (advanced stage), gastric cancer (GC), gastroesophageal junction cancer and 2 more, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity, Recommended Phase 2 Dose up to 24 months and 1 more. Status: unknown.
02
Drugs
SYSA1801
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction cancerpancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05009966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009966.